Global Acquisition Advantage As a Shionogi Group Company with established global reach, Qpex offers opportunities for rapid market access and co-development across regions. This can monetize its anti-infective portfolio by leveraging Shionogi's sales channels, regulatory capabilities, and international partnerships; pursue bundled collaboration or license deals for BRII-693, QPX7728-based assets, and QPX9003.

Resistance Focus Portfolio The focus on multi-drug resistance and a robust beta-lactamase inhibitor and synthetic antibiotic pipeline provides a strong sales narrative to hospitals, ID networks, and government programs seeking novel treatments for resistant infections; target buyers include large health systems, procurement bodies, and national programs for licensing, co-development, or procurement agreements.

China Licensing Opportunity Past licensing in Greater China with Brii Bio demonstrates openness to regional partnerships; opportunities exist to re-engage or expand in China through co-development, local manufacturing, or distribution deals, leveraging local regulatory pathways and available clinical data.

Leadership Momentum With the appointment of President Gareth Morgan, there is momentum to drive strategic BD initiatives, partnerships, and market-entry plans; approach with proposals aligned to growth, including leveraging BARDA relationships and Shionogi channels.

Public Private Partnerships A proven track record with BARDA and active participation in major conferences signals readiness for government-funded opportunities and collaborative R&D programs; target joint development contracts, grants, or milestone-based licensing to accelerate asset progression.